Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ornidazole is a synthetic nitroimidazole derivative and small molecule antiprotozoal and antibacterial agent. It is primarily used to treat infections caused by anaerobic bacteria and protozoa, including trichomoniasis, amebiasis (intestinal and hepatic), giardiasis, bacterial vaginosis, and other susceptible parasitic or bacterial infections. Ornidazole is also used prophylactically to prevent such infections during surgical procedures[1][2][5][6]. Its mechanism of action involves reduction of its nitro group within microbial cells to generate cytotoxic intermediates that interact with DNA, disrupting the helical structure and inhibiting protein synthesis—ultimately leading to cell death in susceptible organisms[5][6]. The drug demonstrates activity against Giardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis, as well as various anaerobic bacteria. Ornidazole is rapidly absorbed orally (bioavailability ~90%), widely distributed in body tissues including cerebrospinal fluid, metabolized in the liver with a half-life of about 13 hours, and excreted mainly via urine as metabolites[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ornidazole.